Skip to main content
Equibles

SLGL · Sol-Gel Technologies Ltd.

Track SLGL — free

Use SLGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SLGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$65.94 -0.85 (-1.27%) At close · Sep 11
Rebalance outlook locked
Market Cap
$215.89M
Shares
3.27M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$65.94 Open$67.42 Day$65.61–67.62 52W close$23.98–97.97 Avg vol 30d67K Short int74K · 2.3% float · 1.1d Short vol47% DataMay 2025–Sep 2026

Raw chart and full-history price indicators begin at the captured split on May 5, 2025; bars on opposite sides are not compared.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+217.7%
Year over year
Operating margin
-38.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
+173.8%
Trailing year
Short interest
2.3%
Latest settlement · 1.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −15%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 57%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −22%
trailing
6-month return −10%
trailing
YTD return +56%
this year
Relative strength −27%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $78 › 200d $70 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$3.9M over 90 days · 0% sells
Short interest Rising
2.26% of float · ▲ +49.3% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
24 holders — near 3-yr high, broad support
Squeeze score 45
elevated · 0–100
Fundamentals
Excellent
Revenue growth +68%
Y/Y
EPS growth +42%
Y/Y
Free cash flow $275.0K
Quant / Vol
risk profile
Very High
Volatility 89%
annualized · 1-yr
Max drawdown −35%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
57% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $78 › 200d $70 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$3.9M over 90 days · 0% sells
Short interest Rising
2.26% of float · ▲ +49.3% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
24 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $24 Now $66 · 57% Range high $98
vs 200-day avg -6% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SLGL
Sol-Gel Technologies Ltd.
this stock
$215.89M +56.5% +68.0% — 2.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
24
% held
40.4%
Net QoQ
+62.1K sh
Top holder
Opaleye Management Inc.
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
74.1K
Days to cover
1.1d
Change
+24.5K sh
View
Short Volume
Short vol %
47%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
3.9K
Value
$327.7K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
26.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$3.9M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$19.4M
Net income (FY)
$-6.1M
EPS diluted
$-2.19
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 20, 2026
This year
4
View
Proposed Sales
Value
$12.6K
Shares
142
Filed
Mar 12, 2026
View

Performance

Raw-price comparisons begin at the captured split on May 5, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
SLGL -5.9% -21.5% -9.6% -4.6% +56.5%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.8% -19.8% -27.5% -4.2% +44.4%
Key facts CIK 1684693 CUSIP M8694L137 13F (30d) 12 filings 12 filers Visit website Investor relations